The primary objective of this R&D project was to design and develop an innovative medical diagnostic process capable of accurately and non-invasively measuring the specific health of the gastrointestinal tract, particularly the colon, to aid in the early detection and monitoring of gut health, autoimmunity, and digestion-related ailments. The envisioned technology aimed to provide clinicians with valuable insights into patients’ health conditions, enabling early detection and precise monitoring of critical medical conditions.
The baseline upon which the advance is being measured is the ability of existing conventional diagnostic imaging systems, such as traditional endoscopy and colonoscopy (which have long been employed for gastrointestinal evaluations) to accurately diagnose gastrointestinal diseases. These procedures, although effective to some extent, pose certain limitations. Traditional endoscopy and colonoscopy often require sedation, causing discomfort and potential risks to patients. Additionally, these procedures may not provide a comprehensive evaluation of the entire gastrointestinal tract, leading to the possibility of missing critical abnormalities and diseases. Furthermore, conventional imaging methods are not always sensitive enough to detect early-stage gut health and autoimmune conditions, resulting in delayed diagnoses and subsequently limited treatment options. As a result, there was an evident need to explore innovative and less invasive approaches to achieve early and precise diagnoses.
Scientific Advancement Achieved
The R&D team undertook an experimentally driven process seeking to advance the understanding and management of gut health, digestion, and autoimmunity. Through comprehensive research and the implementation of innovative laboratory pathology blood tests by establishing direct clinical correlations and determining ideal treatment interventions based on the array tests’ results, significant progress was made in the early detection, monitoring, and treatment of related health conditions.
By developing and integrating specific array tests to measure immune responses and antibodies against various antigens and proteins, the project has provided clinicians with powerful tools to assess gut barrier integrity, detect autoimmune reactions, and identify potential food sensitivities.
Additionally, the incorporation of breath tests to diagnose Small Intestinal Bacterial Overgrowth (SIBO) and the use of colon capsule endoscopy for a non-invasive colonic evaluation have improved diagnostic accuracy and patient comfort. Moreover, the implementation of CCE1 system’s superior imaging capabilities and advanced image processing algorithms facilitated the early detection of gut health issues and autoimmune conditions, enabling timely intervention and tailored treatment plans for patients. This allows for the elimination of sedation significantly improved patient comfort and allowed individuals to resume their daily activities without interruption.